Skin Therapy Letter Home Page DermWebat UBC Subscription Information Index • Volume 3 • Part 1 of 2

	Articles are indexed by drug names, trade-names (marked ®), and disease terms. Bold entries refer to major references.
	Drug name Issue:Page Issue:Page Issue:Page Issue:Page 5 alpha reductase inhibitor 4:2       5 alpha reductase isoenzyme 4:2       5 amino levulinic acid (5ALA) 1:3,4       5 fluorouracil 2:1       13 urea breath test 3:4       A T M Pn 1:3       Abelcet® 4:5       Abrasive procedures 2:4       Accutane® 4:6 5:3,4     Acitretin 4:5 6:1,2     Acne vulgaris 1:4,6 6:1,2     Actinic keratoses 1:3,6 3:5,6     Acyclovir sodium 6:6       Adapalene® 1:6 4:6     Adverse events reports 5:4–6       AIDS Vaccine (Aidsvax®) 6:6       Alatrovafloxacin 5:6       Aldara® 4:5       Allergic reactions 6:5       Alpha hydroxy acid (AHA) 5:1,2       Alpha reductase inhibitor II 4:5       Aminolevulinic acid (ALA) 1:3       Amlexanox 4:5       Amphotericin 4:5       Anaesthetic–topical 4:6       Androgenetic alopecia 4:1,2       Anti HIV drugs 5:6 6:6     Anti-acne 4:5       Antibiotic 5:6       Anti-eczema 4:5       Antifungals 2:6 3:6     Antiherpetics 3:4,5 5:6 6:6   Anti-malarial 6:1       Antimicrobial prophylaxis 2:3–5       Antioxidant 5:6       Drug name Issue:Page Issue:Page Issue:Page Issue:Page Anti-psoriatics 1:6 4:5     Anti-retroviral 5:6       Anti-rosacea 2:6       Anti-seborrheics 1:6       Antiviral prophylaxis 2:4,6       Antivirals 4:5       Aphthasol 4:5       Aphthous ulcers 4:5       Apligraf® 4:5       Artificial skin 1:6 4:5     Aspirin 3:1       Atorvastin calcium® 4:6       Avita® 4:6       Azathioprine 6:1,2       Azelaic acid 3:3       Azelex® 3:3       B P D verteporfin 1:4       Bacteremia 2:4       Bactroban® 3:6       Basal cell carcinoma 6:5       Becaplermin gel 3:6 4:5     Behcet’s disease 3:2       Benzoporphyrin 1:4       Breast implant 2:4       Buffalo humps 5:6       Bullous pemphigoid 3:2       Butenafine Cream 3:6       Cachexia 3:1       Calcipotriene 6:6       Carboxylic acid 5:1       Cardiac pacemakers 2:4       Cephalosporin (Keflex®) 3:2       Chemical Peel 2:3,4 5:1     Chloroquine 3:1       Clobetasol proprionate 1:2       Combivir® 2:6 5:6     Condyloma acuminata 2:1       Corneocyte cohesion 5:1       Corneocyte desquamation 5:1       Corrective dentistry 6:1       Corticosteroids 1:1 6:2     Cosmetics 5:1,2       Crix belly 5:6       Crixivan® 6:6       Cryotherapy 2:1       C-steroid responsive dermatoses 2:6       Cutaneous lichen planus 6:1       Cutaneous sarcoidosis 3:2       Cyclosporine 4:5 6:1,2     Cyproterone 2:6       Drug name Issue:Page Issue:Page Issue:Page Issue:Page Dandruff 1:1,5       Dapsone 6:2       Daunorubicin 4:5       DaunoXome® 4:5       Dear Doctor Letter (Isotretinoin) 5:3       Denavir® 4:5       Depression 5:3–5       Derma Zinc® 1:2,5       Dermabond® 4:6       Dermabrasion 4:6       Dermagraft-TC® 1:6 3:6 4:5   Dermal dystrophy 3:4       Dermalase System® 1:6       Dermatologic surgery 2:3       Dermatophytes 4:3       DHT–mediated disorders 4:5       Diabetic foot ulcers :5       Diane 35® 2:6       Diclofenac gel 1:6 5:6     Dicloxacillin 2:1       Differin® 1:6       Diflucan® 4:4       Dihydrotestosterone (DHT) 4:2       Discoid lupus erythematosus 3:1       Diuretics 6:1       Dovonex® 6:6       Doxycycline 3:4       Dry skin 5:2       Electrocautery 2:1       Emla® 4:6       Endothrix infection 4:4       Enoxaparin 6:2       Epidermal proliferation 5:1       Epidermophyton floccosum 2:6       Er:Cr:Y laser system 1:6       Erythema 2:6       Erythema nodosum leprosum 3:1 6:6     Erythromycin 2:3       Estradiol 4:2       Ethinyl estradiol 2:6 4:6     Extra corporeal phototherapy 6:2       Drug name Issue:Page Issue:Page Issue:Page Issue:Page Facial herpes 2:4       Famciclovir 2:4 6:6     Famvir® 2:4 6:6     Filarial disease 2:5       Finasteride 1:6 3:6 4:1,2,5 6:6 Fluconazole 4:3       Fluticasone 4:5       Genital herpes 2:6       Genital warts 2:2 4:6     Gluconolactone 5:1       Glycolic acid 5:1,2,6       Graft vs host disease 3:1       Graftskin 3:6       Green tinted foundation 3:4       Griseofulvin 4:3,4       Hair loss 2:6       Hair removal lasers 1:4       Helicobacter pylori 3:4       Hemodialysis 2:4       Hepatic disease 6:1       Herpes simplex 2:4 6:2,6     Herpes zoster 6:3,6       Herpetic infections 2:4       High risk patients 2:3       Hirsutism 4:5       HIV infections 2:6       Human skin equiv. 4:5       Hyaluronic acid 5:1       Hydroxychloroquine 6:2       Hyperpigmentation 5:2,6       Hypertrichosis 1:4,6       Hypertrophic scarring 2:4       Ichthyosis 5:2       Idiopathic lichen planus 6:2       Imiquimod 2:1,2 4:5     Immune resp. modifiers 2:1       Immunomodulator 2:1       Immunosuppressives 6:2,5       Indinavir® 6:6       Indomethacin 3:1       Interferon alpha 2:1       Interleukin 2:1       Isotretinoin 4:6 5:3–5     Itraconazole pulse therapy 4:3       Itraconazole 2:6 4:3,4     Ivermectin 2:5       Proceed to Part 2 of 2...

	EDITOR: Stuart Maddin ASSOCIATE EDITOR: David I. McLean INTERNET EDITOR: Harvey Lui PRINCIPAL MEDICAL WRITER: Rodger Hall MANUSCRIPT EDITOR: Rodger Hall  EDITORIAL ADVISORY BOARD: Kenneth A. Arndt, Beth Israel Hospital & Harvard Medical School, Boston; Wilma Fowler Bergfeld, Cleveland Clinic, Cleveland; Jan D. Bos, University of Amsterdam, Amsterdam; Enno Christophers, Universitäts-Hautklinik, Kiel; Hugo Degreef, Catholic University, Leuven; Richard L. Dobson, Medical University of South Carolina, Charleston; Boni E. Elewski, Case Western Reserve University, Cleveland; Barbara A. Gilchrest, Boston University School of Medicine, Boston; W. Andrew D. Griffiths, St. Johns Institute of Dermatology, London; Vincent C.Y. Ho, University of British Columbia, Vancouver; James J. Leyden, University of Pennsylvania, Philadelphia; Howard I. Maibach, University of California Hospital, San Francisco; Larry E. Millikan, Tulane University Medical Center, Louisiana; Takeji Nishikawa, Keio University School of Medicine, Tokyo; Constantin E. Orfanos, Freie Universitäts Berlin, Universitätsklinikum Benjamin Franklin, Berlin; Stephen L. Sacks, Viridae Clinic Sciences, Vancouver; Alan R. Shalita, SUNY Health Sciences Center, Brooklyn; Stephen K. Tyring, University of Texas Medical Branch, Galveston; John Voorhees, University of Michigan, Ann Arbor; Klaus Wolff, University of Vienna, Vienna Skin Therapy Letter®. (ISSN 1201-5989) Copyright 1998 by International Skin Therapy Newsletter Inc. All rights reserved. Reproduction in whole or in part by any process in whole or in part is strictly forbidden without prior consent of the publisher in writing. Published six times yearly by International Skin Therapy Newsletter Inc., 835 West Tenth Avenue, Vancouver, British Columbia, Canada V5Z 4E8. Tel: (604) 874-6112. Fax: (604) 873-9919. Annual subscription: Canadian $85 individual; $155 institutional (GST included). US $60 individual; $110 institutional. Outside North America: US$80 individual; $130 institutional. Quotes on multiple subscriptions and student rates supplied upon request. Skin Therapy Letter •Editor: Dr. Stuart Maddin •Index to Volume 3
	Return to Top